- Home
- SENEA vs SVRA Comparison
SENEA vs SVRA Comparison
Compare SENEA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- SVRA
- Stock Information
- Founded
- SENEA 1949
- SVRA 2007
- Country
- SENEA United States
- SVRA United States
- Employees
- SENEA N/A
- SVRA N/A
- Industry
- SENEA Packaged Foods
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- SENEA Consumer Staples
- SVRA Health Care
- Exchange
- SENEA Nasdaq
- SVRA Nasdaq
- Market Cap
- SENEA 629.3M
- SVRA 528.3M
- IPO Year
- SENEA N/A
- SVRA N/A
- Fundamental
- Price
- SENEA $94.31
- SVRA $2.28
- Analyst Decision
- SENEA
- SVRA Buy
- Analyst Count
- SENEA 0
- SVRA 7
- Target Price
- SENEA N/A
- SVRA $7.57
- AVG Volume (30 Days)
- SENEA 16.4K
- SVRA 2.5M
- Earning Date
- SENEA 06-12-2025
- SVRA 05-13-2025
- Dividend Yield
- SENEA N/A
- SVRA N/A
- EPS Growth
- SENEA 25.61
- SVRA N/A
- EPS
- SENEA 5.45
- SVRA N/A
- Revenue
- SENEA $1,541,031,000.00
- SVRA N/A
- Revenue This Year
- SENEA N/A
- SVRA N/A
- Revenue Next Year
- SENEA N/A
- SVRA N/A
- P/E Ratio
- SENEA $17.31
- SVRA N/A
- Revenue Growth
- SENEA 4.00
- SVRA N/A
- 52 Week Low
- SENEA $51.79
- SVRA $1.89
- 52 Week High
- SENEA $94.86
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- SENEA 62.77
- SVRA 36.20
- Support Level
- SENEA $89.47
- SVRA $1.89
- Resistance Level
- SENEA $94.11
- SVRA $3.18
- Average True Range (ATR)
- SENEA 2.40
- SVRA 0.21
- MACD
- SENEA 0.26
- SVRA -0.11
- Stochastic Oscillator
- SENEA 94.51
- SVRA 29.77
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.